Characteristic | MTX Monotherapy | LEF Monotherapy | MTX + LEF | Neither* |
---|---|---|---|---|
N (%) | 1552 (52.2) | 217 (7.3) | 415 (13.9) | 791 (26.6) |
Sex, % | ||||
Female | 72.7 | 75.9 | 72.7 | 76.7 |
Male | 27.3 | 24.1 | 27.3 | 23.3 |
Mean age, yrs (SD) | 63.0 (13.8) | 63.0 (12.8) | 60.0 (12.8) | 62.0 (13.7) |
DAS28 available, n (%) | 892 (57) | 100 (46) | 228 (54) | 235 (29) |
DAS28, mean (SD) | 2.9 (1.2) | 3.2 (1.2) | 3.3 (1.4) | 2.8 (1.3) |
Other medications | ||||
Prednisone, % | 34.0 | 37.3 | 39.3 | 22.9 |
Prednisone daily dose, mean (SD) | 6.8 (6.2) | 5.4 (2.6) | 6.5 (4.0) | 7.4 (5.9) |
NSAID | 19.4 | 14.7 | 19.5 | 15.5 |
Comorbidities, % | ||||
Viral hepatitis | 0.1 | 0.5 | 0.0 | 0.3 |
Other liver disease | 0.5 | 3.7 | 0.5 | 1.1 |
Diabetes | 4.6 | 4.6 | 4.1 | 4.4 |
Steatohepatitis | 0.2 | 0.9 | 0.0 | 0.3 |
Blood disorders | 2.3 | 1.8 | 2.9 | 4.3 |
Infectious diseases | 0.8 | 0.0 | 1.9 | 1.0 |
↵* Nonbiologic disease-modifying antirheumatic drug other than MTX and LEF. MTX: methotrexate; LEF: leflunomide; DAS: Disease Activity Score; NSAID: nonsteroidal antiinflammatory drug.